Literature DB >> 21928348

Nemo-like kinase inhibits osteoblastogenesis by suppressing bone morphogenetic protein and WNT canonical signaling.

Stefano Zanotti1, Ernesto Canalis.   

Abstract

The bone morphogenetic protein/Signaling mothers against decapentaplegic (BMP/Smad) and the WNT signaling pathways regulate the commitment of mesenchymal cells to the osteoblastic lineage. Nemo-like kinase (Nlk) is an evolutionary conserved kinase that suppresses Smad transactivation and WNT canonical signaling. However, it is not clear whether these effects of Nlk have any consequence on the differentiation of mammalian cells. To study the function of Nlk during the commitment of ST-2 bone marrow stromal cells to the osteoblastic fate, Nlk was downregulated by RNA interference (RNAi), following transfection of a specific small interfering (si)RNA. Nlk downregulation increased alkaline phosphatase and osteocalcin expression and sensitized ST-2 cells to the effects of BMP2 and WNT3 on alkaline phosphatase mRNA expression and activity. Accordingly, Nlk downregulation enhanced the effect of BMP2 on the transactivation of the BMP/Smad reporter construct 12xSBE-Oc-pGL3, and on the levels of phosphorylated Smad1/5/8, whereas it did not affect the transactivation of the transforming growth factor-β/Smad reporter pSBE-Luc. Nlk downregulation sensitized ST-2 cells to the effects of WNT3 on the transactivation of the WNT/T-cell factor (Tcf) reporter construct 16xTCF-Luc, whereas it did not affect cytosolic β-catenin levels. To understand the function of Nlk in cells committed to the osteoblastic lineage, Nlk was suppressed by RNAi in primary calvarial osteoblasts. Downregulation of Nlk increased alkaline phosphatase and osteocalcin transcripts and sensitized osteoblasts to the effects of BMP2 on alkaline phosphatase activity and Smad1/5/8 transactivation and phosphorylation. In conclusion, Nlk suppresses osteoblastogenesis by opposing BMP/Smad and WNT canonical signaling.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21928348      PMCID: PMC3253257          DOI: 10.1002/jcb.23365

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  40 in total

Review 1.  RNA interference--2001.

Authors:  P A Sharp
Journal:  Genes Dev       Date:  2001-03-01       Impact factor: 11.361

2.  Multiplex quantitative PCR using self-quenched primers labeled with a single fluorophore.

Authors:  Irina Nazarenko; Brian Lowe; Marlene Darfler; Pranvera Ikonomi; David Schuster; Ayoub Rashtchian
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

3.  Effect of primary and secondary structure of oligodeoxyribonucleotides on the fluorescent properties of conjugated dyes.

Authors:  Irina Nazarenko; Rick Pires; Brian Lowe; Mohamad Obaidy; Ayoub Rashtchian
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

4.  The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways.

Authors:  Anja Nohe; Sylke Hassel; Marcelo Ehrlich; Florian Neubauer; Walter Sebald; Yoav I Henis; Petra Knaus
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

5.  Abnormal bone marrow stroma in mice deficient for nemo-like kinase, Nlk.

Authors:  M Kortenjann; M Nehls; A J Smith; R Carsetti; J Schüler; G Köhler; T Boehm
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

6.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

Review 7.  Distantly related cousins of MAP kinase: biochemical properties and possible physiological functions.

Authors:  Y Miyata; E Nishida
Journal:  Biochem Biophys Res Commun       Date:  1999-12-20       Impact factor: 3.575

8.  Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling.

Authors:  Tohru Ishitani; Jun Ninomiya-Tsuji; Kunihiro Matsumoto
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

Review 9.  Marrow stromal stem cells.

Authors:  P Bianco; P Gehron Robey
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

10.  Homodimerization of Nemo-like kinase is essential for activation and nuclear localization.

Authors:  Shizuka Ishitani; Kenji Inaba; Kunihiro Matsumoto; Tohru Ishitani
Journal:  Mol Biol Cell       Date:  2010-11-30       Impact factor: 4.138

View more
  6 in total

1.  Upregulation of cell proliferation via Shc and ERK1/2 MAPK signaling in SaOS-2 osteoblasts grown on magnesium alloy surface coating with tricalcium phosphate.

Authors:  Tianlong Jiang; Lei Guo; Shenghui Ni; Yuyan Zhao
Journal:  J Mater Sci Mater Med       Date:  2015-03-18       Impact factor: 3.896

2.  Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer.

Authors:  Maolan Li; Shenglai Zhang; Zhiqiang Wang; Bingtai Zhang; Xiangsong Wu; Hao Weng; Qian Ding; Zhujun Tan; Ning Zhang; Jiasheng Mu; Jiahua Yang; Yijun Shu; Runfa Bao; Qichen Ding; Wenguang Wu; Yang Cao; Yingbin Liu
Journal:  Tumour Biol       Date:  2013-07-16

Review 3.  Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches.

Authors:  Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2013-08-13       Impact factor: 43.330

4.  Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes.

Authors:  Stefano Zanotti; Ernesto Canalis
Journal:  Bone       Date:  2017-07-01       Impact factor: 4.398

5.  Nemo-like kinase regulates postnatal skeletal homeostasis.

Authors:  Ernesto Canalis; Lauren Kranz; Stefano Zanotti
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

6.  TCF-1 participates in the occurrence of dedifferentiated chondrosarcoma.

Authors:  Xiaolong Xu; Xiaodong Tang; Wei Guo; Kang Yang; Tingting Ren
Journal:  Tumour Biol       Date:  2016-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.